丹麦制药商诺和诺德周三表示，得益于其Wegovy减重药片的销售，公司上调了全年预测，因为它继续争取在肥胖症市场占据更大份额。
Nordisk A/S boosted its forecast for the year, citing sales of its Wegovy weight-loss pill as it continues to fight for a larger share of the obesity market.
该公司称，按固定汇率计算，今年销售额和利润最高可增长2%。最坏情况现在是下降2%。诺和诺德此前曾表示，按固定汇率计算，今年销售额和利润将持平至下降6%。
Both sales and profit could rise as much as 2% this year at constant exchange rates, the Danish drugmaker said Wednesday. The worst-case scenario is now a 2% decline. Novo had previously said its sales and profit would be flat to 6% lower this year, at constant exchange rates.
诺和诺德正在不断增长的全球减重药物市场上与礼来公司竞争。今年丹麦公司凭借Wegovy药片取得了一场胜利，迄今该药片表现优于礼来自家的口服产品，但投资者担心诺和诺德的下一代药物将无法达到其美国竞争对手所提供的水平。礼来上周因其药物需求激增而上调了预测。
Novo is battling Eli Lilly & Co. in the growing global market for weight-loss medicines. The Danish company had a win this year with its Wegovy pill, which so far is beating Lilly’s own oral offering, but investors worry that its next-generation medicines will fall short of what its US rival has to offer. Lilly raised its forecast last week on surging demand for its drugs.
诺和诺德还宣布任命新任首席财务官，表示Galderma Group AG的Luigi La Corte将接替Karsten Munk Knudsen。作为在诺和诺德工作27年的资深员工，Knudsen将留任至12月底。
Novo also announced a new chief financial officer, saying that Galderma Group AG’s Luigi La Corte will succeed Karsten Munk Knudsen. Knudsen, a 27-year Novo veteran, will remain through the end of December.
一些分析师指出，处方趋势显示诺和诺德的药片销售正在趋于平稳。花旗分析师写道，截至10月23日当周，药片处方的四周滚动平均值持平。
Some analysts have suggested that prescription trends show Novo’s pill sales are flattening out. In the week ending Oct. 23, pill prescriptions showed a flat four-week rolling average, Citi analysts wrote.
这家制药商的中期增长前景在很大程度上取决于一种名为CagriSema的下一代注射剂，该药物在临床试验中带来的减重效果未达投资者预期。今年以来诺和诺德股价下跌17%，而礼来股价上涨31%。
The drugmaker’s outlook for medium-term growth depends heavily on a next-generation shot called CagriSema, which has failed to deliver as much weight loss as investors expected in clinical trials. Novo’s shares have dropped 17% so far this year, while Lilly’s gained 31%.